$RGEN
REPLIGEN CORP Stock $rgen

$rgen Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-K Financial Statement

#000119312515095569 Filed on March 17, 2015

Income Statement

Concept	2013 Q4	2013 Q3	2013 Q2
Revenue	$15.38M	$18.82M	$17.51M
YoY Change	-18.24%	24.62%	12.79%
Cost Of Revenue	$4.627M	$5.659M	$5.298M
YoY Change	-21.84%	-11.84%	-27.87%
Gross Profit	$10.76M	$13.16M	$12.21M
YoY Change	-16.59%	51.56%	49.3%
Gross Profit Margin	69.92%	69.93%	69.74%
Selling, General & Admin	$3.367M	$2.902M	$3.124M
YoY Change	3.5%	-7.17%	-8.6%
% of Gross Profit	31.31%	22.05%	25.58%
Research & Development	$1.422M	$1.430M	$2.306M
YoY Change	-39.31%	-41.22%	-20.65%
% of Gross Profit	13.22%	10.86%	18.88%
Depreciation & Amortization	$840.0K	$760.0K	$690.0K
YoY Change	-8.7%	-14.61%	-21.59%
% of Gross Profit	7.81%	5.77%	5.65%
Operating Expenses	$4.789M	$4.332M	$5.430M
YoY Change	-14.42%	-22.07%	-14.14%
Operating Profit	$5.183M	$8.042M	$6.103M
YoY Change	-19.15%	267.55%	363.05%
Interest Expense	$100.0K	$11.70K	$12.40K
YoY Change	614.29%	-267.2%	-54.67%
% of Operating Profit	1.93%	0.15%	0.2%
Other Income/Expense, Net	-$54.00K	$37.00K	-$122.0K
YoY Change	31.71%	-107.4%	-126.64%
Pretax Income	$5.215M	$8.143M	$6.034M
YoY Change	-18.74%	354.92%	239.37%
Income Tax	$1.887M	$2.255M	$1.495M
% Of Pretax Income	36.18%	27.69%	24.78%
Net Earnings	$3.328M	$5.888M	$4.539M
YoY Change	-65.16%	226.02%	189.11%
Net Earnings / Revenue	21.64%	31.28%	25.92%
Basic Earnings Per Share	$0.10	$0.18	$0.14
Diluted Earnings Per Share	$0.10	$0.18	$0.14
COMMON SHARES
Basic Shares Outstanding	31.92M shares	31.86M shares	31.64M shares
Diluted Shares Outstanding	32.71M shares	32.55M shares	32.32M shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$61.60M	$63.00M	$58.10M
YoY Change	53.62%	107.92%	104.58%
Cash & Equivalents	$39.83M	$42.24M	$37.33M
Short-Term Investments	$21.80M	$20.70M	$20.80M
Other Short-Term Assets	$33.35K	$1.500M	$2.000M
YoY Change	-9.2%	36.36%	81.82%
Inventory	$11.80M	$10.06M	$10.56M
Prepaid Expenses
Receivables	$4.946M	$6.324M	$4.871M
Other Receivables	$6.800M	$6.600M	$5.300M
Total Short-Term Assets	$86.35M	$87.44M	$80.91M
YoY Change	30.42%	62.55%	54.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.51M	$12.29M	$9.838M
YoY Change	25.69%	21.5%	-0.31%
Goodwill	$994.0K	$994.0K	$994.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles	$6.188M	$6.482M	$6.499M
YoY Change	-13.85%	-12.13%	-9.44%
Long-Term Investments	$12.20M	$4.100M	$4.600M
YoY Change	23.23%	-66.94%	-57.8%
Other Assets	$400.0K	$300.0K	$1.800M
YoY Change	-85.71%	50.0%	800.0%
Total Long-Term Assets	$32.29M	$24.20M	$23.74M
YoY Change	4.85%	-22.21%	-18.39%
TOTAL ASSETS
Total Short-Term Assets	$86.35M	$87.44M	$80.91M
Total Long-Term Assets	$32.29M	$24.20M	$23.74M
Total Assets	$118.6M	$111.6M	$104.7M
YoY Change	22.3%	31.5%	28.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.721M	$929.6K	$1.481M
YoY Change	-29.86%	-47.38%	-42.7%
Accrued Expenses	$9.580M	$7.855M	$8.738M
YoY Change	15.45%	8.06%	22.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.30M	$8.784M	$10.22M
YoY Change	5.11%	-2.78%	4.99%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.458M	$2.696M	$1.984M
YoY Change	62.08%	41.86%	-27.68%
Total Long-Term Liabilities	$3.458M	$2.696M	$1.984M
YoY Change	62.08%	41.86%	-27.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.30M	$8.784M	$10.22M
Total Long-Term Liabilities	$3.458M	$2.696M	$1.984M
Total Liabilities	$14.76M	$11.48M	$12.20M
YoY Change	14.54%	4.97%	-2.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$89.06M	-$92.38M	-$98.27M
YoY Change	-15.3%	-19.45%	-15.65%
Common Stock	$190.9M	$318.8K	$318.1K
YoY Change	61110.19%	2.67%	3.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$84.12M	$100.2M	$92.45M
YoY Change
Total Liabilities & Shareholders Equity	$118.6M	$111.6M	$104.7M
YoY Change	22.3%	31.5%	28.49%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2013 Q2
OPERATING ACTIVITIES
Net Income	$3.328M	$5.888M	$4.539M
YoY Change	-65.16%	226.02%	189.11%
Depreciation, Depletion And Amortization	$840.0K	$760.0K	$690.0K
YoY Change	-8.7%	-14.61%	-21.59%
Cash From Operating Activities	$6.960M	$6.580M	$8.800M
YoY Change	-3.73%	166.4%	337.81%
INVESTING ACTIVITIES
Capital Expenditures	-$860.0K	-$2.660M	-$790.0K
YoY Change	100.0%	731.25%	125.71%
Acquisitions
YoY Change
Other Investing Activities	-$9.160M	$600.0K	$20.00K
YoY Change	-356.58%	-161.22%	-98.85%
Cash From Investing Activities	-$10.03M	-$2.070M	-$760.0K
YoY Change	-419.43%	60.47%	-155.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	660.0K	-170.0K	1.070M
YoY Change	144.44%	-122.37%	5250.0%
NET CHANGE
Cash From Operating Activities	6.960M	6.580M	8.800M
Cash From Investing Activities	-10.03M	-2.070M	-760.0K
Cash From Financing Activities	660.0K	-170.0K	1.070M
Net Change In Cash	-2.410M	4.340M	9.110M
YoY Change	-122.65%	123.71%	167.16%
FREE CASH FLOW
Cash From Operating Activities	$6.960M	$6.580M	$8.800M
Capital Expenditures	-$860.0K	-$2.660M	-$790.0K
Free Cash Flow	$7.820M	$9.240M	$9.590M
YoY Change	2.09%	231.18%	306.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31925741	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31925741	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.07
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2013Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4005174	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1610988	shares
CY2013Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	183000
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16571000
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12287010
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	103886102
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3457631
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	599784
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118644904
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2404802
CY2013Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1195248
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	385478
CY2013Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1648928
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11301171
CY2013Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	44000
CY2013Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	2028000
CY2013Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2324711
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	319257
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1998330
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1721459
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-89057422
CY2013Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	7591
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	190625937
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9579712
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3341
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1917247
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3166086
CY2013Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1897473
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	10000
CY2013Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4637
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39829653
CY2013Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	21647
CY2013Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	2116017
CY2013Q4	us-gaap	Goodwill Goodwill	994000
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12509223
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	34012152
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16802000
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1249824
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	200000
CY2013Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	184848
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3018000
CY2013Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	12218602
CY2013Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	32294305
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2955120
CY2013Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	6730818
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24796233
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12264000
CY2013Q4	us-gaap	Assets Assets	118644904
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	187000
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	231000
CY2013Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	1984
CY2013Q4	us-gaap	Interest Receivable InterestReceivable	214902
CY2013Q4	us-gaap	Inventory Net InventoryNet	11798638
CY2013Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4557870
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4946132
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	34017451
CY2013Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9936
CY2013Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	21793550
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1520000
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6187632
CY2013Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	8973615
CY2013Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	13684954
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	33350
CY2013Q4	us-gaap	Prepaid Insurance PrepaidInsurance	344698
CY2013Q4	us-gaap	Prepaid Taxes PrepaidTaxes	135102
CY2013Q4	us-gaap	Assets Current AssetsCurrent	86350599
CY2013Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	8592434
CY2013Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4285648
CY2013Q4	rgen	Prepaid Services And Professional Fees PrepaidServicesAndProfessionalFees	521772
CY2014Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	357399
CY2014Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1370000
CY2014Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	1090736
CY2014Q2	us-gaap	Goodwill Goodwill	13190835
CY2014Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	84662
CY2014Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	26539660
CY2014Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	1646746
CY2014Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	184080
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32774374	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32774374	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	723010	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.31
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	412500	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.31
CY2014Q4	us-gaap	Share Price SharePrice	19.80
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	723010	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	10.40
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	41	Investment
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2780057	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1225117	shares
CY2014Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	78000
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17298000
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13815697
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	4414000
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10682413
CY2014Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	251000
CY2014Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	1956068
CY2014Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	571080
CY2014Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2080566
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	327744
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5773142
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3863350
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-80887208
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1439000
CY2014Q4	us-gaap	Contractual Obligation ContractualObligation	2835000
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	198064414
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6819063
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	111731808
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5879013
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	712919
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	14045000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1422000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1930000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	128293234
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3443570
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1135061
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	511588
CY2014Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	16498000
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	3844574
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	129904
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2080566
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2420000
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3758511
CY2014Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	274000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2420000
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	40644
CY2014Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6403
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1782000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1697000
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14636307
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35363024
CY2014Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	3847746
CY2014Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	2270347
CY2014Q4	us-gaap	Goodwill Goodwill	14184835
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14526240
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	14261197
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	26640419
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	23666285
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17431000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	1759000
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2103576
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	450000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	6969962
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3069000
CY2014Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	485670
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	1595000
CY2014Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	3550210
CY2014Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	47347592
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6377000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	1580000
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4753508
CY2014Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	239890
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	28341937
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6391377
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	23089499
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12580000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	1759000
CY2014Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	418831
CY2014Q4	us-gaap	Assets Assets	128293234
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-118000
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	133000
CY2014Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	4928
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4143883
CY2014Q4	us-gaap	Interest Receivable InterestReceivable	99802
CY2014Q4	us-gaap	Inventory Net InventoryNet	12383633
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5373860
CY2014Q4	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	0
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7760382
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	9400
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	26643408
CY2014Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9392
CY2014Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	23090209
CY2014Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	9108214
CY2014Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	13115630
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	27774
CY2014Q4	us-gaap	Prepaid Insurance PrepaidInsurance	359062
CY2014Q4	us-gaap	Prepaid Taxes PrepaidTaxes	220029
CY2014Q4	us-gaap	Assets Current AssetsCurrent	80945642
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	23090209
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	18079877
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2256265
CY2014Q4	rgen	Available For Sale Securities Debt Maturities One Through Two Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesOneThroughTwoYearsAmortizedCost	3553909
CY2014Q4	rgen	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	3550210
CY2014Q4	rgen	Prepaid Services And Professional Fees PrepaidServicesAndProfessionalFees	492408
CY2014Q4	rgen	Impact Of Credit Risk On Fair Value Of Derivatives ImpactOfCreditRiskOnFairValueOfDerivatives	0
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32777774	shares
CY2014Q2	dei	Entity Public Float EntityPublicFloat	744293642
CY2011Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	200000
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	65987000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11167745
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.20
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2315090	shares
CY2012Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	329000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	84124596
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29209821
CY2014Q2	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	26539660
CY2014Q2	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	21169660
CY2014Q2	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	4000000
CY2014Q2	rgen	Business Acquisition Working Capital Adjustments BusinessAcquisitionWorkingCapitalAdjustments	-66277
CY2007Q2	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	0.01
CY2007Q2	rgen	Stock Issued During Period Shares Common Stock Warrants StockIssuedDuringPeriodSharesCommonStockWarrants	150000	shares
CY2007Q2	rgen	Warrant Term WarrantTerm	P7Y
CY2014Q1	rgen	Lease Commencement Date LeaseCommencementDate	2014-08-01
CY2014Q1	rgen	Lease Agreement Term LeaseAgreementTerm	P8Y1M
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.50
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5139	pure
CY2013	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	739626	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.31
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.301	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.053	pure
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	25929967
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2013	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	0.56
CY2013	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	1589000
CY2013	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-2399697
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	1264000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.049	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0221	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0109	pure
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32406641	shares
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.51
CY2013	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P8Y
CY2013	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	0.58
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.5363	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0208	pure
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	187000	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31667015	shares
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	991000
CY2013	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	105771
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	10231223
CY2013	us-gaap	Gain Loss On Investments GainLossOnInvestments	0
CY2013	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	47482382
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-57604
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	625895
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	23013821
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2522185
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	22873240
CY2013	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-1836
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	16179515
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	23013821
CY2013	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	16403000
CY2013	us-gaap	Royalty Revenue RoyaltyRevenue	20687241
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-110648
CY2013	us-gaap	Revenues Revenues	68169623
CY2013	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	42480331
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4634776
CY2013	us-gaap	Net Income Loss NetIncomeLoss	16093155
CY2013	us-gaap	Investment Income Net InvestmentIncomeNet	301078
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	773954
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1059806
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-19411
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	12782598
CY2013	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	76331000
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2787967
CY2013	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	73970
CY2013	us-gaap	Interest Expense InterestExpense	49849
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7340698
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12701195
CY2013	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	91191
CY2013	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	71964
CY2013	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	3322032
CY2013	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1201660
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1022000
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	10619832
CY2013	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-1227747
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	7824699
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6920666
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2437000
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	22481122
CY2013	us-gaap	Depreciation Depreciation	2092000
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3113892
CY2013	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	2682177
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2522184
CY2013	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	1305388
CY2013	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1256736
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-17906289
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2450220
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4123752
CY2013	us-gaap	Costs And Expenses CostsAndExpenses	45296383
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1121821
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-733728
CY2013	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	29208818
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	1059806
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3723000
CY2013	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	2293245
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-508629
CY2013	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	8707
CY2013	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	800000
CY2013	rgen	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	-298185
CY2013	rgen	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.013	pure
CY2013	rgen	Provision For Deferred Income Tax Expense Benefit ProvisionForDeferredIncomeTaxExpenseBenefit	2796914
CY2013	rgen	Deferred Tax Assets Valuation Allowance Increase Decrease DeferredTaxAssetsValuationAllowanceIncreaseDecrease	-1736000
CY2013	rgen	Income Tax Expense Benefit Continuing Operation IncomeTaxExpenseBenefitContinuingOperation	6920665
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5100	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	420698	shares
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y7M21D
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.41
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Entity Registrant Name EntityRegistrantName	REPLIGEN CORP
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014	dei	Trading Symbol TradingSymbol	RGEN
CY2014	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	766010	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.41
CY2014	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.267	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.132	pure
CY2014	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y3M4D
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><font style="font-family:Times New Roman" size="2"><b>1.</b></font></td> <td align="left" valign="top"><font style="font-family:Times New Roman" size="2"><b>Organization and Nature of Business</b></font></td> </tr> </table> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">Repligen Corporation (“Repligen” or the “Company”) is a life sciences company that develops, manufactures and markets high-value, consumable bioprocessing products for life sciences companies and biopharmaceutical manufacturing companies worldwide. The Company is a world-leading manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. Repligen also supplies several growth factor products, ATF System products and cell filtration products used to increase cell culture productivity during the bioproduction process. In the expanding area of flexible biomanufacturing technologies, the Company has developed and currently markets a series of OPUS chromatography columns for use in clinical-scale manufacturing. The Company generally manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sells its chromatography columns, as well as media and quality test kits, and ATF products directly to biopharmaceutical companies or contract manufacturing organizations or through distributors. Repligen refers to these activities as its bioprocessing business. The Company manufactures its products in production facilities in the United States and Sweden.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"> <font style="font-family:Times New Roman" size="2">Historically, Repligen also conducted activities aimed at developing proprietary therapeutic drug candidates, often with a potential of entering into a collaboration with a larger commercial stage pharmaceutical or biotechnology company in respect of these programs. In addition, the Company has out-licensed certain intellectual property to Bristol-Myers Squibb Company, from which Repligen received royalties on Bristol’s net sales in the United States of their product Orencia<font style="font-family:Times New Roman" size="1"><sup style="vertical-align:baseline; position:relative; bottom:.8ex">®</sup></font>. On April 7, 2008, the Company entered into a settlement agreement with Bristol in connection with a patent infringement lawsuit that Repligen filed against Bristol. Under the terms of the settlement agreement, Bristol was obligated to pay us royalties on its U.S. net sales of Orencia<font style="font-family:Times New Roman" size="1"><sup style="vertical-align:baseline; position:relative; bottom:.8ex">®</sup></font> for any clinical indication at a rate of 1.8% for the first $500,000,000 of annual sales, 2.0% for the next $500,000,000 of annual sales and 4% of annual sales in excess of $1 billion. Under the terms of the agreement, Repligen will not receive any future royalties on Bristol’s sales of Orencia<font style="font-family:Times New Roman" size="1"><sup style="vertical-align:baseline; position:relative; bottom:.8ex">®</sup></font> made after December 31, 2013. As part of Repligen’s strategic decision in 2012 to focus the Company’s efforts on its core bioprocessing business, the Company reduced efforts on its clinical development programs and increased its efforts to find collaboration partners to finish their development and, if successful, commercialize these therapeutic drug candidates.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The Company is subject to a number of risks typically associated with companies in the biotechnology industry. These risks principally include the Company’s dependence on key customers, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with the FDA and other governmental regulations and approval requirements, as well as the ability to grow the Company’s business and obtain adequate funding to finance this growth.</font></p> </div>
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	18401298
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2014	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	0.27
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.011	pure
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Significant estimates and assumptions by management affect the Company’s revenue recognition for multiple element arrangements, allowance for doubtful accounts, the net realizable value of inventory, estimated fair value of cost method investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets and goodwill, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, stock-based compensation, contingent liabilities, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</font></p> </div>
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0650	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002	pure
CY2014	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0188	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.49
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33263667	shares
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.25
CY2014	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y9M
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	105831	shares
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.98
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0000730272
CY2014	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	0.28
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.5171	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0211	pure
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	860124
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	307475	shares
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><b>Concentrations of Credit Risk and Significant Customers</b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. Per the Company’s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings and credit exposure to any one issue, issuer (with the exception of U.S. treasury obligations) and type of instrument is limited. At December 31, 2014 and 2013, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential write-off of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers’ financial condition.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">Revenue from significant customers as a percentage of the Company’s total revenue is as follows:</font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">  </p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"> <tr> <td width="81%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" colspan="10" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>Years ended December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Orencia<font style="font-family:Times New Roman" size="1"><sup style="vertical-align:baseline; position:relative; bottom:.8ex">®</sup></font> Royalties from Bristol</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td nowrap="nowrap" valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">—  </font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">27</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">24</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">GE Healthcare</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">38</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">35</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">42</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Bioprocessing Customer B</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">20</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">12</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">10</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Bioprocessing Customer C</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">13</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">13</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">10</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> </tr> </table> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">Significant accounts receivable balances as a percentage of the Company’s total trade accounts receivable and royalties and other receivable balances are as follows:</font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">  </p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"> <tr> <td width="70%"></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>December 31, 2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>December 31, 2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">GE Healthcare</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">29</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">42</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Customer D</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">11</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">0</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td> </tr> </table> </div>
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	700738	shares
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32497657	shares
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	125000
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1084000
CY2014	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-7743699
CY2014	us-gaap	Increase In Restricted Cash IncreaseInRestrictedCash	250000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	12290567
CY2014	us-gaap	Gain Loss On Investments GainLossOnInvestments	0
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	60431508
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	820060
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2735000
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	28022034
CY2014	us-gaap	Depreciation Depreciation	2594000
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4019387
CY2014	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	13190835
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17154555
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5608693
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11138583
CY2014	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2071994
CY2014	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	4000000
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1680432
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	10691073
CY2014	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-35028
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	398742
CY2014	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	0
CY2014	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-6557205
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	2547000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	11138583
CY2014	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	1370000
CY2014	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	9493000
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	38319
CY2014	us-gaap	Royalty Revenue RoyaltyRevenue	3116841
CY2014	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	21235937
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	188000
CY2014	us-gaap	Revenues Revenues	63548349
CY2014	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	27507599
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5602547
CY2014	us-gaap	Net Income Loss NetIncomeLoss	8170214
CY2014	us-gaap	Investment Income Net InvestmentIncomeNet	309467
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1596803
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1766532
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-27773
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1151984
CY2014	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	67330000
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	295095
CY2014	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	2115000
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-4756129
CY2014	us-gaap	Interest Expense InterestExpense	49957
CY2014	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2071994
CY2014	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	1246348
CY2014	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	214274
CY2014	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1036082
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1425000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4466629
CY2014	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-1470662
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3787118
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2968369
CY2014	rgen	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	-171921
CY2014	rgen	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.015	pure
CY2014	rgen	Provision For Deferred Income Tax Expense Benefit ProvisionForDeferredIncomeTaxExpenseBenefit	487760
CY2014	rgen	Royalty Payment Rate RoyaltyPaymentRate	0.15	pure
CY2014	rgen	Lease Agreement Area LeaseAgreementArea	45000	sqft
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1680431
CY2014	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-67383
CY2014	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2489152
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-19792229
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1680431
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2480609
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	52857276
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	121561
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2288064
CY2014	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	34803854
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1766532
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10474833
CY2014	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	139000
CY2014	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	2821478
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	727157
CY2014	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-24884
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0
CY2014	rgen	Long Term Marketable Securities Maturities Term Minimum LongTermMarketableSecuritiesMaturitiesTermMinimum	P1Y
CY2014	rgen	Number Of Buildings Leased NumberOfBuildingsLeased	4	Building
CY2014	rgen	Payment To Be Received Upon Signing Of Agreement PaymentToBeReceivedUponSigningOfAgreement	125675
CY2014	rgen	Deferred Tax Assets Valuation Allowance Increase Decrease DeferredTaxAssetsValuationAllowanceIncreaseDecrease	727000
CY2014	rgen	Nonrefundable Upfront Cash Payment Under Collaborations Agreement NonrefundableUpfrontCashPaymentUnderCollaborationsAgreement	2000000
CY2014	rgen	Marketable Securities Remaining Maturity MarketableSecuritiesRemainingMaturity	P7Y8M12D
CY2014	rgen	Income Tax Expense Benefit Continuing Operation IncomeTaxExpenseBenefitContinuingOperation	2968369
CY2001	rgen	Lease Agreement Area LeaseAgreementArea	25000	sqft
CY2001	rgen	Lease Agreement Term LeaseAgreementTerm	P10Y
CY2007	rgen	Lease Agreement Area LeaseAgreementArea	2500	sqft
CY2007	rgen	Lease Agreement Term LeaseAgreementTerm	P5Y
CY2011	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-05-31
CY2011	rgen	Lease Agreement Area LeaseAgreementArea	55694	sqft
CY2011	rgen	Lease Agreement Term LeaseAgreementTerm	P11Y
CY2008	rgen	Lease Agreement Area LeaseAgreementArea	7350	sqft
CY2008	rgen	Lease Agreement Term LeaseAgreementTerm	P2Y
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.45
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.4976	pure
CY2012	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	339010	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.62
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.256	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001	pure
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	13439608
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.032	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.6450	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.013	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0089	pure
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31253434	shares
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.5354	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0106	pure
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1296700	shares
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30914424	shares
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	931000
CY2012	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1790551
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	95768
CY2012	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	41834188
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-30266
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2734239
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11271406
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1159064
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	11083113
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	15954380
CY2012	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	314244
CY2012	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	803000
CY2012	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	5923675
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	140000
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	11271406
CY2012	us-gaap	Royalty Revenue RoyaltyRevenue	20432348
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	26403
CY2012	us-gaap	Revenues Revenues	62266536
CY2012	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	39109959
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1263647
CY2012	us-gaap	Net Income Loss NetIncomeLoss	14156037
CY2012	us-gaap	Investment Income Net InvestmentIncomeNet	218604
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1211343
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1024152
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7792
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	11175638
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3143268
CY2012	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	602523
CY2012	us-gaap	Interest Expense InterestExpense	56714
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10489811
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13226732
CY2012	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	610877
CY2012	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-2915673
CY2012	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1110791
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1017000
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	18042076
CY2012	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-8332
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3944996
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2884631
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2183000
CY2012	us-gaap	Cost Of Goods Sold CostOfGoodsSold	24957243
CY2012	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	3021000
CY2012	us-gaap	Depreciation Depreciation	2492000
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3508592
CY2012	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	2213004
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1159064
CY2012	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	115307
CY2012	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2083964
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	2840881
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1159064
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	312630
CY2012	us-gaap	Costs And Expenses CostsAndExpenses	51183423
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	357866
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1001546
CY2012	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	43214487
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	1024152
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1384000
CY2012	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-84265
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-7272092
CY2012	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-149698
CY2012	rgen	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	242629
CY2012	rgen	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.021	pure
CY2012	rgen	Provision For Deferred Income Tax Expense Benefit ProvisionForDeferredIncomeTaxExpenseBenefit	-3197261
CY2012	rgen	Cumulative Pretax Loss Position Period CumulativePretaxLossPositionPeriod	P3Y
CY2012	rgen	Deferred Tax Assets Valuation Allowance Increase Decrease DeferredTaxAssetsValuationAllowanceIncreaseDecrease	-10169000
CY2012	rgen	Income Tax Expense Benefit Continuing Operation IncomeTaxExpenseBenefitContinuingOperation	-2884631
CY2013	us-gaap	Gain Loss On Investments GainLossOnInvestments	0
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2013Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31855000	shares
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2013Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31241000	shares
CY2013Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-14000
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	11934000
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3545000
CY2013Q1	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0
CY2013Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	62000
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	3622000
CY2013Q1	us-gaap	Royalty Revenue RoyaltyRevenue	4522000
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	29000
CY2013Q1	us-gaap	Revenues Revenues	16456000
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	2338000
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1121000
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6335000
CY2014Q1	us-gaap	Costs And Expenses CostsAndExpenses	11018000
CY2014Q1	rgen	Non Contingent Consideration Being Recognized As Revenue Over Estimated Period Of Performance NonContingentConsiderationBeingRecognizedAsRevenueOverEstimatedPeriodOfPerformance	2000000
CY2014Q1	rgen	Change In Fair Value Of Acquisition Related Contingent Consideration ChangeInFairValueOfAcquisitionRelatedContingentConsideration	98000
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32317000	shares
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31644000	shares
CY2013Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-12000
CY2013Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	13014000
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	6103000
CY2013Q2	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0
CY2013Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	65000
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	6034000
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2183000
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3308000
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1284000
CY2013Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6897000
CY2013Q1	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	577000
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	12911000
CY2013Q1	rgen	Change In Fair Value Of Acquisition Related Contingent Consideration ChangeInFairValueOfAcquisitionRelatedContingentConsideration	-54000
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31855000	shares
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31963000	shares
CY2014Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-14000
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	14335000
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	5308000
CY2014Q1	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0
CY2014Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	102000
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5398000
CY2014Q1	us-gaap	Royalty Revenue RoyaltyRevenue	1991000
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000
CY2014Q1	us-gaap	Revenues Revenues	16326000
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	4277000
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1201000
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3384000
CY2013Q2	us-gaap	Royalty Revenue RoyaltyRevenue	4495000
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-122000
CY2013Q2	us-gaap	Revenues Revenues	17509000
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	4539000
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2306000
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	5183000
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3124000
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1495000
CY2013Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5298000
CY2013Q2	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	643000
CY2013Q2	us-gaap	Costs And Expenses CostsAndExpenses	11406000
CY2013Q2	rgen	Change In Fair Value Of Acquisition Related Contingent Consideration ChangeInFairValueOfAcquisitionRelatedContingentConsideration	35000
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33076000	shares
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32234000	shares
CY2014Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-13000
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	15551000
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	3106000
CY2014Q2	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0
CY2014Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	85000
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	3243000
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	65000
CY2014Q2	us-gaap	Revenues Revenues	15551000
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	2825000
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1430000
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4326000
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	418000
CY2014Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6671000
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	12445000
CY2014Q2	rgen	Change In Fair Value Of Acquisition Related Contingent Consideration ChangeInFairValueOfAcquisitionRelatedContingentConsideration	18000
CY2013Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2013Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32708000	shares
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
CY2013Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31916000	shares
CY2013Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-12000
CY2013Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	10350000
CY2013Q4	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0
CY2013Q4	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	98000
CY2013Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5215000
CY2013Q4	us-gaap	Royalty Revenue RoyaltyRevenue	5032000
CY2013Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-54000
CY2013Q4	us-gaap	Revenues Revenues	15382000
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	3328000
CY2013Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1422000
CY2013Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3367000
CY2013Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1887000
CY2013Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4627000
CY2013Q4	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	738000
CY2013Q4	us-gaap	Costs And Expenses CostsAndExpenses	10199000
CY2013Q4	rgen	Change In Fair Value Of Acquisition Related Contingent Consideration ChangeInFairValueOfAcquisitionRelatedContingentConsideration	45000
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2014Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32747000	shares
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2014Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32747000	shares
CY2014Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-12000
CY2014Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	15393000
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	61000
CY2014Q4	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0
CY2014Q4	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	59000
CY2014Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	242000
CY2014Q4	us-gaap	Royalty Revenue RoyaltyRevenue	1000000
CY2014Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	134000
CY2014Q4	us-gaap	Revenues Revenues	16393000
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-398000
CY2014Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1328000
CY2014Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4975000
CY2014Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	640000
CY2014Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	8084000
CY2014Q4	us-gaap	Costs And Expenses CostsAndExpenses	16332000
CY2014Q4	rgen	Change In Fair Value Of Acquisition Related Contingent Consideration ChangeInFairValueOfAcquisitionRelatedContingentConsideration	1945000
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.18
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32552000	shares
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.18
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31858000	shares
CY2013Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-12000
CY2013Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	12184000
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	8042000
CY2013Q3	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0
CY2013Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	76000
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	8143000
CY2013Q3	us-gaap	Royalty Revenue RoyaltyRevenue	6638000
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	37000
CY2013Q3	us-gaap	Revenues Revenues	18822000
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	5888000
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1430000
CY2013Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2902000
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2255000
CY2013Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5659000
CY2013Q3	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	724000
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	10780000
CY2013Q3	rgen	Change In Fair Value Of Acquisition Related Contingent Consideration ChangeInFairValueOfAcquisitionRelatedContingentConsideration	65000
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33327000	shares
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32677000	shares
CY2014Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-11000
CY2014Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	15153000
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	2216000
CY2014Q3	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0
CY2014Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	64000
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2255000
CY2014Q3	us-gaap	Royalty Revenue RoyaltyRevenue	125000
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14000
CY2014Q3	us-gaap	Revenues Revenues	15278000
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	1466000
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1650000
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4471000
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	789000
CY2014Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6931000
CY2014Q3	us-gaap	Costs And Expenses CostsAndExpenses	13062000
CY2014Q3	rgen	Change In Fair Value Of Acquisition Related Contingent Consideration ChangeInFairValueOfAcquisitionRelatedContingentConsideration	10000

Files In Submission

Name	View Source	Status
0001193125-15-095569-index-headers.html	Edgar Link	pending
0001193125-15-095569-index.html	Edgar Link	pending
0001193125-15-095569.txt	Edgar Link	pending
0001193125-15-095569-xbrl.zip	Edgar Link	pending
d854858d10k.htm	Edgar Link	pending
d854858dex1016.htm	Edgar Link	pending
d854858dex211.htm	Edgar Link	pending
d854858dex231.htm	Edgar Link	pending
d854858dex311.htm	Edgar Link	pending
d854858dex312.htm	Edgar Link	pending
d854858dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g854858g56j16.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgen-20141231.xml	Edgar Link	completed
rgen-20141231.xsd	Edgar Link	pending
rgen-20141231_cal.xml	Edgar Link	unprocessable
rgen-20141231_def.xml	Edgar Link	unprocessable
rgen-20141231_lab.xml	Edgar Link	unprocessable
rgen-20141231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGEN
REPLIGEN CORP Stock $rgen

2013 Q4 Form 10-K Financial Statement

#000119312515095569 Filed on March 17, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGEN REPLIGEN CORP Stock $rgen

2013 Q4 Form 10-K Financial Statement

#000119312515095569 Filed on March 17, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGEN
REPLIGEN CORP Stock $rgen